<DOC>
	<DOCNO>NCT01634243</DOCNO>
	<brief_summary>The primary objective trial establish maximum maintenance dose SPM 962 patient Parkinson 's disease multi-center , uncontrolled , open-label study conduct safety evaluation patient follow once-daily transdermal dos SPM 962 within range 4.5 36.0 mg. ( The administration period consist standard 8-week dose-titration period , 4-week dose-maintenance period , dose de-escalation period ) Exploratory evaluation patient 's maintenance dose also conduct attention patient safety . The relationship pharmacokinetics , safety , efficacy also examine .</brief_summary>
	<brief_title>A Dose-ranging Study SPM 962 Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>For subject early advance Parkinson 's disease Subject diagnose Parkinson 's disease accordance `` Diagnostic Criteria establish Research Committee MHLWspecified Intractable Neurodegenerative Diseases ( 1995 ) '' . Subject 30 less 80 year age time informed consent . Gender inpatientoutpatient status specify . For subject early Parkinson 's disease Hoehn &amp; Yahr stage 3 less . Subject take Ldopa within 28 day prior initial administration SPM 962 . For subject dvanced Parkinson 's disease Hoehn &amp; Yahr stage 24 . Subject stable dose Ldopa change daily dose dose regimen least 7 day prior initial treatment SPM 962 . Subject follow problematic symptom ; 1 ) Wearing phenomenon 2 ) On phenomenon 3 ) Not well control Ldopa due adverse effect 4 ) Weakening Ldopa efficacy . Subject dopamine agonist treatment within 7 day prior initial treatment . Subject cabergoline treatment within 14 day prior initial treatment . Subject psychiatric symptom , e.g . confusion , hallucination , delusion , excitation , delirium , abnormal behavior . Subject orthostatic hypotension . Subject history epilepsy , convulsion . Subject complication serious cardiac disorder history . Subject arrhythmia treat class 1a antiarrhythmic drug ( e.g . quinidine , procainamide etc . ) class 3 antiarrhythmic drug ( e.g . amiodarone , sotalol etc. ) . At screen baseline , subject develop serious ECG abnormality . Subjects QTcinterval &gt; 450 msec screening . Subject QTcinterval &gt; 450 msec male &gt; 470 msec female baseline . Subject congenital long QT syndrome . Subject hypokalaemia . Subject total bilirubin &gt; = 3.0 mg/dL AST ( GOT ) ALT ( GPT ) great 2.5 time upper limit reference range ( &gt; = 100 IU/L ) . Subject BUN &gt; = 25 mg/dL serum creatinine &gt; = 2.0 mg/dl . Subject history allergic reaction topical agent transdermal patch . Subject pregnant nursing woman plan pregnancy trial . Subject receive therapy prohibit drug specify study protocol . Subject history pallidotomy , thalamotomy , deep brain stimulation fetal tissue transplant . Subject dementia . Subject unable give consent . Subject participate another trial investigational drug do within 6 month prior initial treatment . Investigator judge subject inappropriate study subject reason .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>SPM 962</keyword>
	<keyword>rotigotine</keyword>
	<keyword>Parkinson 's disease</keyword>
</DOC>